Biomea Fusion, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $99.3M
- Price
- $1.37
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.74%
- Volume
- 575.3K
About
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Quick stats
Shares outstanding72.5M
Computed float65.1M
Float / shares89.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840439
Websitehttps://biomeafusion.com
AI Summary
AI-generated1/11
standardbullishclinical trial
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion dosed the first patient in a new arm of the OPAL study evaluating its investigational drug icovamenib in combination with low-dose semaglutide for obesity.
The randomized, double-blind study aims to enroll 64 participants to assess whether adding icovamenib can enhance weight loss and improve physical function and body composition compared to semaglutide alone.
Preclinical data suggests the combination improves weight reduction through fat loss while preserving lean mass, supporting the potential for a differentiated metabolic health treatment.